Athena: Specialty Certificate Examination Case for Formulation and Systemic Therapy

August 2023 in “ Clinical and Experimental Dermatology ”

Gia T Tang, Adam Daunton

TLDR The document discusses a special exam case for formulating and using systemic therapy named Athena.

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on academic.oup.com →

Discuss this study in the Community →

Related Community Posts Join

6 / 1000+ results

community An Uncontrolled Case Series Using a Botanically Derived, β-Cyclodextrin Inclusion Complex in Two Androgenetic Alopecia-Affected Male Subjects

in Research/Science 1 upvotes 5 years ago

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

community Best Treatment In The Pipeline?

in Chat 15 upvotes 2 years ago

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

community Anagenic is trying to compound Gt20029

in Treatment 56 upvotes 3 years ago

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

community EMA is re-examining Winlevi (clascoterone at lower concentration)

in Treatment 8 upvotes 1 year ago

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

community Trial for TDM-105795 update from research office

in Research/Science 17 upvotes 2 years ago

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

community Spiro for AGA in Europe

5 upvotes 6 years ago

Treatment options for female alopecia androgenetica, discussing the availability of spironolactone online in The Netherlands and other potential treatments like finasteride, minoxidil and RU58841.